PT - JOURNAL ARTICLE AU - Lilie, Tyler AU - Bouzy, Jennifer AU - Asundi, Archana AU - Taylor, Jessica AU - Roche, Samantha AU - Olson, Alex AU - Coxen, Kendyll AU - Corry, Heather AU - Jordan, Hannah AU - Clayton, Kiera AU - Lin, Nina AU - Tsibris, Athe TI - HIV-1 latency reversal agent boosting is not limited by opioid use AID - 10.1101/2023.05.26.23290576 DP - 2024 Jan 01 TA - medRxiv PG - 2023.05.26.23290576 4099 - http://medrxiv.org/content/early/2024/06/04/2023.05.26.23290576.short 4100 - http://medrxiv.org/content/early/2024/06/04/2023.05.26.23290576.full AB - The opioid epidemic may impact the HIV-1 reservoir and its reversal from latency in virally suppressed people with HIV (PWH). We studied forty-seven PWH and observed that lowering the concentration of HIV-1 latency reversal agents (LRA), used in combination with small molecules that do not reverse latency, synergistically increases the magnitude of HIV-1 re-activation ex vivo, regardless of opioid use. This LRA boosting, which combines a Smac mimetic or low-dose protein kinase C agonist with histone deacetylase inhibitors, can generate significantly more unspliced HIV-1 transcription than phorbol 12-myristate 13-acetate (PMA) with ionomycin (PMAi), the maximal known HIV-1 reactivator. LRA boosting associated with greater histone acetylation in CD4+ T cells and modulated T cell activation-induced markers and intracellular cytokine production; Smac mimetic-based boosting was less likely to induce immune activation. We found that HIV-1 reservoirs in PWH contain unspliced and polyadenylated (polyA) virus mRNA, the ratios of which are greater in resting than total CD4+ T cells and can correct to 1:1 with PMAi exposure. Latency reversal results in greater fold-change increases to HIV-1 poly(A) mRNA than unspliced message. Multiply spliced HIV-1 transcripts and virion production did not consistently increase with LRA boosting, suggesting the presence of a persistent post-transcriptional block. LRA boosting can be leveraged to probe the mechanisms of an effective cellular HIV-1 latency reversal program.Competing Interest StatementAthe Tsibris has received remuneration or lab funding from Gilead Sciences, Merck & Co, and EBSCO-Dynamed. Nina Lin is an employee of Moderna, Inc.Funding StatementThis work is supported by the NIH R61 DA047038 and R33 DA047038 and was facilitated by the Providence/Boston CFAR (P30AI042853) and the Harvard University CFAR (P30AI060354. The project was further supported by Clinical Translational Science Award 1UL1TR002541.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Institutional review board at Boston Medical Center and the Massachusetts General Brigham Human Research CommitteeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors